Alpha Tau Medical Ltd Cl A (DRTS)

$4.23 +0.02 (0.48%)
Market Cap 357.09M
Revenue (ttm) 0.00
Net Income (ttm) -31.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.07
Volume 28,600
Avg Vol 60,964
Day's Range N/A - N/A
Shares Out 84.82M
Stochastic %K 81%
Beta 1.07
Analysts Strong Sell
Price Target $8.67

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 577 4115
Address:
Kiryat HaMada St. 5, Jerusalem, Israel
JarvisFlow
JarvisFlow Oct. 22 at 2:41 PM
HC Wainwright & Co. has updated their rating for Alpha Tau Medical ( $DRTS ) to Buy with a price target of 9.
0 · Reply
WallStWireAds
WallStWireAds Oct. 22 at 12:38 PM
$DRTS https://thefinanceherald.com/the-next-breakthrough-in-cancer-treatment-might-not-be-a-drug-at-all/
0 · Reply
StonkCrasher420
StonkCrasher420 Oct. 21 at 9:24 PM
$DRTS Just opened a nice intro position here. Very excited about what this company does and the potential it has. Does anyone know why it’s such a ghost town in here? Shoutout to the people on Reddit getting eyes onto this.
1 · Reply
5IVE42
5IVE42 Oct. 21 at 8:49 PM
$DRTS $6 on the table in November
0 · Reply
WallStWireAds
WallStWireAds Oct. 20 at 9:49 PM
$DRTS https://seekingalpha.com/article/4830482-alpha-tau-medical-localized-alpha-radiation-a-new-paradigm-in-oncology#source=section%3Asummary%7Csection_asset%3Aall_analysis%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1
0 · Reply
JohnStocksNY
JohnStocksNY Oct. 8 at 1:43 PM
If you are new to $DRTS, and even if you’re a long time investor, this is a great updated overview of everything going on, from understanding what the company actually does to what you can expect going forward. https://youtu.be/uuMeK_eE2Bc?si=2BSxCF8QoekyioSZ
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 5:39 PM
$DRTS Really good write-up that perfectly summarizes DRTS's present situation. So if you want to bring your DRTS knowledge up to date or just discover DRTS, this is required reading. https://beyondspx.com/quote/DRTS/analysis/alpha-tau-medical-pioneering-precision-alpha-radiation-in-oncology-nasdaq-drts
0 · Reply
WallStWireAds
WallStWireAds Oct. 3 at 3:54 PM
$DRTS https://capnotes.beehiiv.com/p/alpha-tau-medical-builds-toward-inflection-point-as-cancer-trials-regulatory-catalysts-and-market-in
0 · Reply
LoveNvidia
LoveNvidia Oct. 3 at 2:50 AM
Looks like volume & momentum could be shifting in to ASTC! Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $DRTS $BLMN $EBET $HIVE __
2 · Reply
Nickb1977
Nickb1977 Sep. 30 at 9:15 PM
$DRTS 52 week high today. Incredibly thinly traded, but some decent volume towards the end of the day.
1 · Reply
Latest News on DRTS
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 21, 2025, 8:30 AM EDT - 4 days ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 17, 2025, 10:04 AM EDT - 8 days ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Oct 16, 2025, 11:55 AM EDT - 9 days ago

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Sep 2, 2025, 8:30 AM EDT - 7 weeks ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau to Participate in Five September Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 2 months ago

Alpha Tau to Participate in Five September Investor Conferences

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:02 PM EDT - 2 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jul 25, 2025, 9:04 AM EDT - 3 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:01 PM EDT - 5 months ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 12, 2025, 4:01 PM EDT - 5 months ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Alpha Tau to Participate in May Investor Conferences

May 6, 2025, 8:30 AM EDT - 6 months ago

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 6 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 6 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Apr 2, 2025, 8:30 AM EDT - 7 months ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:02 PM EDT - 8 months ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24, 2025, 8:30 AM EST - 8 months ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 9:00 AM EST - 9 months ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18, 2024, 8:30 AM EST - 11 months ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17, 2024, 9:00 AM EST - 11 months ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:30 AM EST - 11 months ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 6, 2024, 8:30 AM EST - 11 months ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:45 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 20, 2024, 4:01 PM EDT - 1 year ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

May 6, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 25, 2024, 8:50 AM EDT - 1 year ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 1 year ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 26, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 20, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 16, 2023, 4:30 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Nov 13, 2023, 8:00 AM EST - 2 years ago

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Oct 30, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 28, 2023, 4:02 PM EDT - 2 years ago

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Medical to Participate in September Investor Conferences

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Alpha Tau Medical to Participate in September Investor Conferences

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Aug 17, 2023, 5:00 PM EDT - 2 years ago

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

Aug 2, 2023, 9:00 AM EDT - 2 years ago

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

Alpha Tau Medical to Participate in June Investor Conferences

May 24, 2023, 4:01 PM EDT - 2 years ago

Alpha Tau Medical to Participate in June Investor Conferences

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 23, 2023, 4:01 PM EDT - 2 years ago

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 17, 2023, 4:30 PM EDT - 2 years ago

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

May 11, 2023, 4:00 PM EDT - 2 years ago

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

JarvisFlow
JarvisFlow Oct. 22 at 2:41 PM
HC Wainwright & Co. has updated their rating for Alpha Tau Medical ( $DRTS ) to Buy with a price target of 9.
0 · Reply
WallStWireAds
WallStWireAds Oct. 22 at 12:38 PM
$DRTS https://thefinanceherald.com/the-next-breakthrough-in-cancer-treatment-might-not-be-a-drug-at-all/
0 · Reply
StonkCrasher420
StonkCrasher420 Oct. 21 at 9:24 PM
$DRTS Just opened a nice intro position here. Very excited about what this company does and the potential it has. Does anyone know why it’s such a ghost town in here? Shoutout to the people on Reddit getting eyes onto this.
1 · Reply
5IVE42
5IVE42 Oct. 21 at 8:49 PM
$DRTS $6 on the table in November
0 · Reply
WallStWireAds
WallStWireAds Oct. 20 at 9:49 PM
$DRTS https://seekingalpha.com/article/4830482-alpha-tau-medical-localized-alpha-radiation-a-new-paradigm-in-oncology#source=section%3Asummary%7Csection_asset%3Aall_analysis%7Cfirst_level_url%3Asymbol%7Cbutton%3ATitle%7Clock_status%3ANo%7Cline%3A1
0 · Reply
JohnStocksNY
JohnStocksNY Oct. 8 at 1:43 PM
If you are new to $DRTS, and even if you’re a long time investor, this is a great updated overview of everything going on, from understanding what the company actually does to what you can expect going forward. https://youtu.be/uuMeK_eE2Bc?si=2BSxCF8QoekyioSZ
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 5:39 PM
$DRTS Really good write-up that perfectly summarizes DRTS's present situation. So if you want to bring your DRTS knowledge up to date or just discover DRTS, this is required reading. https://beyondspx.com/quote/DRTS/analysis/alpha-tau-medical-pioneering-precision-alpha-radiation-in-oncology-nasdaq-drts
0 · Reply
WallStWireAds
WallStWireAds Oct. 3 at 3:54 PM
$DRTS https://capnotes.beehiiv.com/p/alpha-tau-medical-builds-toward-inflection-point-as-cancer-trials-regulatory-catalysts-and-market-in
0 · Reply
LoveNvidia
LoveNvidia Oct. 3 at 2:50 AM
Looks like volume & momentum could be shifting in to ASTC! Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $DRTS $BLMN $EBET $HIVE __
2 · Reply
Nickb1977
Nickb1977 Sep. 30 at 9:15 PM
$DRTS 52 week high today. Incredibly thinly traded, but some decent volume towards the end of the day.
1 · Reply
TheHookingBull
TheHookingBull Sep. 26 at 9:05 PM
$DRTS thoughts on price target with Japan approval?
2 · Reply
TheHookingBull
TheHookingBull Sep. 25 at 7:54 PM
$DRTS when are results from first pancreatic patient expected?
2 · Reply
Nickb1977
Nickb1977 Sep. 25 at 11:31 AM
$DRTS pre-market up nicely. 10.3k shares traded, but I don’t remember the last time we had this much pre-market activity on drts.
0 · Reply
Doozio
Doozio Sep. 23 at 2:01 AM
$JXN is gonna be throwing $DRTS wen Roger is rocking n RAVEing with his Nabers 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Sep. 20 at 2:44 PM
$DRTS in the YO as POWL has started that RAVE 🐒🍌🧠⏰♾️
0 · Reply
docone
docone Sep. 19 at 5:27 PM
$DRTS let’s hope news is leaking for Japan makes sense stock should then move to the 20s
0 · Reply
Team_Zissou
Team_Zissou Sep. 19 at 4:53 PM
$DRTS Biotech is getting beat up today, why the strength here? News leaking on approval in Japan?
0 · Reply
Nickb1977
Nickb1977 Sep. 19 at 4:40 PM
$DRTS putting the cart before the horse here, but if they get PMDA approval, thoughts on valuation here? Doesn’t it feel like the sky is the limit and why would anyone sell their stock at less than $3-5b ($30-50/share)? Obviously a significant # of hurdles with execution, but this also becomes an immediate, albeit cheap, takeout target.
1 · Reply
JohnStocksNY
JohnStocksNY Sep. 16 at 10:46 AM
$DRTS some major catalysts coming with first pancreatic cancer patient successfully treated in the US, GBM next, PMDA approval in Japan and more
0 · Reply
WallStWireAds
WallStWireAds Sep. 8 at 12:47 PM
$DRTS https://alphacatalyst.beehiiv.com/p/alpha-tau-medical-reaches-major-milestone-first-u-s-patient-treated-in-pancreatic-cancer-trial-nasda
0 · Reply
docone
docone Sep. 6 at 4:47 PM
$DRTS it appears we will have profit from not only manufacturing but also on a per treatment basis I like they keeping it in house
0 · Reply
docone
docone Sep. 5 at 7:07 PM
$DRTS approval in Japan should be almost immediate revenue
0 · Reply